At Takeda Oncology, we aspire to cure #cancer. Below, hear from our leaders about how we’re positioned to elevate the standard of cancer care for patients globally through our cutting-edge science, strategic partnerships and programs that enable access to our medicines. To learn more, visit: www.takedaoncology.com
About us
Takeda Oncology, the Global Oncology Business Unit of Takeda Pharmaceutical Company Limited, is structured to ensure a tight connection from research to development to commercialization and rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to market. Built on a legacy foundation and structured for agility, our leaders have proven experience to drive future growth. We’ve demonstrated leadership in the treatment of hematologic cancers and solid tumors, and we’re now leveraging that expertise to advance cutting-edge science through multiple platforms, partnerships and therapeutic approaches. We are focused on collaborating with leading scientific teams around the globe to accelerate remarkable innovation, including by leveraging the power of innate immunity to enhance and broaden the impact of immunotherapy. We complement our deep in-house expertise with a network of symbiotic external partnerships to unlock the most promising science wherever it emerges. We fuel our relationships with academic, biotechnology and pharmaceutical partners with mutual respect, shared knowledge, scientific rigor and agility to find the best way to attack cancer. Takeda Oncology: We aspire to cure cancer, with inspiration from patients and innovation from everywhere. For more information, visit www.takedaoncology.com. If you are interested in learning more about current career opportunities, please visit the Takeda Pharmaceuticals Career Page. Review our social media community guidelines: https://www.takedaoncology.com/social-media-policy/
- Website
-
http://www.takedaoncology.com
External link for Takeda Oncology
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1,001-5,000 employees
- Headquarters
- Cambridge, MA
- Type
- Public Company
- Founded
- 1993
- Specialties
- oncology, drug development, and biotechnology
Locations
-
Primary
40 Landsdowne St.
Cambridge, MA 02139, US
Employees at Takeda Oncology
Updates
-
We had a great time at the Pan-Mass Challenge this weekend. Thank you to our riders for cycling to cure cancer, all our colleagues who volunteered and to those who cheered us on! See #TeamTakeda in action at #PMC2024 below!
-
-
We are pleased to enter a new partnership with BostonGene, a leading provider of #ArtificialIntelligence (AI)-driven molecular and immune profiling solutions. This partnership will enable us to use cutting-edge technology to better understand our investigational therapies at the earliest stages, optimizing their development for people living with #cancer. Find out more: https://lnkd.in/g3kJes6f
-
-
#TeamTakeda is back on the road for the 2024 Pan-Mass Challenge! Hear why representing #TeamTakeda at the #PMC2024 is more than just a ride for Julie. #OneInABillion #WhyIRide
For team members like Julie, riding with #TeamTakeda allows her to embrace two important identities within the #cancer community as both a dedicated professional and caring family member. Hear why she's proud to honor her brother Ryan at this year’s Pan-Mass Challenge. #PMC2024 | #OneInABillion
-
We’re pleased to share the European Commission has approved a therapy for adult patients with previously treated metastatic #ColorectalCancer (#mCRC) throughout the European Union, Iceland, Liechtenstein and Norway. Learn more about this announcement: https://lnkd.in/gJjVNcut
-
With more effective options than ever before, there is a greater need to collectively evolve how we select #cancer treatments for individuals with varied life experiences. See why Awny Farajallah, MD, FACP, Chief Medical Officer, Global Oncology, says the future of cancer care considers real-world factors alongside traditional clinical standards: https://lnkd.in/ePms_URR
-
-
We’ve announced an option agreement with Ascentage Pharma that will allow us to enter into a future exclusive global license agreement for its investigational therapy currently in development for #ChronicMyeloidLeukemia (CML) and other #HematologicalCancers. If exercised, the option would allow Takeda to secure rights to develop and commercialize the therapy in all indications and territories outside of mainland China, Hong Kong, Macau, Taiwan and Russia. Read more here: https://lnkd.in/emdra3rS
Takeda Signs Option Agreement with Ascentage Pharma
takedaoncology.com
-
Cancer is a looming threat that affects all of us, with incidence projected to increase over the next 25 years, according to the American Cancer Society. Awny Farajallah, MD, FACP, Chief Medical Officer, Global Oncology, says we need solutions now. Read more about how we can bring these solutions to patients faster by rethinking #ClinicalTrial design. Learn more in STAT: https://lnkd.in/evpx8r-x
-
A difficult decision is always the right one if it aligns with your #values. Pallavi Garg, Head, Global Oncology Products and Pipeline Strategy, shares how, amidst the rapid pace of change in #healthcare, our team's collective purpose, vision and values continue to persevere. Learn how we let our ethics and values inspire a sense of urgency and guide our path to curing #cancer: https://lnkd.in/dw8izTZe
-
As the #oncology landscape continues to evolve, it’s important to keep a pulse on the diverse perspectives of the #cancer community and continuously assess how we can improve our approach to patient-centered care. Stefanie Granado, Head, US Oncology Business Unit, sat down with leaders from Colorectal Cancer Alliance and ALK Positive Inc. at #ASCO2024 to discuss how we can better understand the priorities of patients throughout all stages of their journeys and use these insights to inform care. Read Stefanie’s takeaways from the conversation below:
One of the many reasons I love attending #ASCO is the opportunity to connect with patients and advocates firsthand. They are at the heart of our work, and it’s imperative we hear from them directly to best understand the evolving and diverse needs, priorities, and perspectives of patients across walks of life and stages of treatment. This past Friday, I had the honor of moderating a discussion with Marianne Pearson of Colorectal Cancer Alliance and Kirk Smith of ALK Positive Inc., who were gracious enough to share their perspectives on how far we’ve come – and the important work left to do – in cancer care. I want to thank Marianne, Kirk, and their organizations for all that they do. Your advocacy is incredibly impactful and I’m inspired by how you’re using your experiences and expertise to make a difference for patients. As the landscape of #cancer care evolves, continuing to connect with patients and advocates is critical to the work that we do in #oncology; not only are we able to gain insights about their lived experiences, but we can also better understand the real-world priorities of people living with cancer. These learnings allow us to identify the most pressing needs of our patients and work to support their treatment experience and long-term goals. Thank you, Marianne and Kirk, for sharing your perspective and joining me for this robust discussion! #ASCO24
-